FCGBP inhibits the development of LSCC and cisplatin resistance through the PIGR/JAK2/STAT3 pathway. Radiol Oncol. 2026;60(1):67-75. Accessed September 20, 2026. https://radioloncol.com/index.php/ro/article/view/4672